Humira Will Get Advisory Committee Review For Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee is scheduled to review Abbott’s sNDA for the TNF blocker Humira Aug. 28.
You may also be interested in...
FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.
Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis
Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.